asco gu poster session 2017.eisenhauer ea therasse p bogaerts j schwartz lh sargent d ford r dancey j arbuck s gwyther s mooney m rubinstein l shankar l dodd l kaplan r lacombe d and verweij j new response evaluation criteria in solid tumours revised recist guideline version 1.1. eur j cancer 452 228-247 2009.daillere r vetizou m waldschmitt n yamazaki t isnard c poirier-colame v duong cp flament c lepage p roberti mp routy b jacquelot n apetoh l becharef s rusakiewicz s langella p sokol h kroemer g enot d roux a eggermont a tartour e johannes l woerther pl chachaty e soria jc golden e formenti s plebanski m madondo m rosenstiel p raoult d cattoir v boneca ig chamaillard m and zitvogel l enterococcus hirae and barnesiella intestinihominis facilitate cyclophosphamide-induced therapeutic immunomodulatory effects.

curr oncol 19suppl 1 s52-s58 2012.brahmer j reckamp kl baas p crino l eberhardt we poddubskaya e antonia s pluzanski a vokes ee holgado e waterhouse d ready n gainor j aren frontera o havel l steins m garassino mc aerts jg domine m paz-ares l reck m baudelet c harbison ct lestini b and spigel dr nivolumab versus docetaxel in advanced squamous-cell non- small-cell lung cancer.

n engl j med 3732 123-135 2015.borghaei h paz-ares l horn l spigel dr steins m ready ne chow lq vokes ee felip e holgado e barlesi f kohlhaufl m arrieta o burgio ma fayette j lena h poddubskaya e gerber de gettinger sn rudin cm rizvi n crino l blumenschein gr jr. antonia sj dorange c harbisonct graf finckenstein f and brahmer jr nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer.

science 3506264 1084-1089 2015.derosa l routy b enot d baciarello g massard c loriot y fizazi k escudier bj zitvogel l and albiges l impact of antibiotics on outcome in patients with metastatic renal cell carcinoma treated with immune checkpoint inhibitors.

type of atb therapymonotherapy11 73.3bi-therapy4 26.7route of atb administrationoral11 73.3 intravenous4 26.7duration of atb treatment7 days7 46.77 days8 53.3location of infectionpulmonary10 66.6urinary3 20.0catheter1 6.7other1 6.7time between atb exposure and first nivolumab1-3 months8 53.31 month5 33.4during nivolumab treatment2 13.3were also collected from medical records and concerned type of antibiotic medication route of administration duration of exposure infection location and time between antibiotic exposure and first nivolumab injection.

concerning best response to nivolumab treatment23 of patients 1774 experienced partial pr or complete response cr 28.4 2174 stable disease sd and 48.6 3674 progressive disease pd.only 15 20.3 patients were exposed to antibiotic medication in the 3 months before first nivolumab injection or during treatment.

moreover we found no impact of antibiotic medication on pfs under nivolumab log-rank test p0.72 figure 1. univariate cox proportional hazards model indicated that no clinical factor was significantly associated with improved pfs table iii.figure 1. kaplan-meier curves of progression-free survival under nivolumab therapy according to antibiotic use.

science 3366086 1268-1273 2012.viaud s daillere s boneca ig lepage p langella p chamaillard m pittet mj ghiringhelli f trinchieri g goldszmid r and zitvogel l gut microbiome and anticancer immune response really hot sht cell death differ 222 199- 214 2015.boursi b mamtani r haynes k and yang yx recurrent antibiotic exposure may promote cancer formation-another step in understanding the role of the human microbiota eur j cancer 5117 2655-2664 2015.iida n dzutsev a stewart ca smith l bouladoux n weingarten ra molina da salcedo r back t cramer s dai rm kiu h cardone m naik s patri ak wang e marincola fm frank km belkaid y trinchieri g and goldszmid rs commensal bacteria control cancer response to therapy by modulating the tumor microenvironment.

science 3426161 967-970 2013.viaud s saccheri f mignot g yamazaki t daillere r hannani d enot dp pfirschke c engblom c pittet mj schlitzer a ginhoux f apetoh l chachaty e woerther pl eberl g berard m ecobichon c clermont d bizet c gaboriau-routhiau v cerf-bensussan n opolon p yessaad n vivier e ryffel b elson co dore j kroemer g lepage p boneca ig ghiringhelli f and zitvogel l the intestinal microbiota modulates the anticancer immune effects of cyclophosphamide.

immunity 454 931-943 2016.zitvogel l galluzzi l smyth mj and kroemer g mechanism of action of conventional and targeted anticancer therapies reinstating immunosurveillance.

immunity 391 74-88 2013.galluzzi l buque a kepp o zitvogel l and kroemer g immunological effects of conventional chemotherapy and targeted anticancer agents.

we examined whether antibiotic usage could impact nivolumab efficacy in patients treated for non-small-cell lung cancer nsclc.

they received nivolumab between 2015 and 2016 3 mgkg i.v.

results a total of 17 21 and 36 patients experienced response stable disease and progression disease under nivolumab.

only 15 20.3 patients were exposed to antibiotic medication in the 3 months before the first nivolumab injection or during treatment.

